Transgenic mice expressing exon 1 of the human Huntington's disease (HD) gene carrying a 141-157 CAG repeat (line R6/2) develop a progressive neurological phenotype with motor symptoms resembling those seen in HD. We have characterized the motor deficits in R6/2 mice using a battery of behavioral tests selected to measure motor aspects of swimming, fore- and hindlimb coordination, balance, and sensorimotor gating [swimming tank, rotarod, raised beam, fore- and hindpaw footprinting, and acoustic startle/prepulse inhibition (PPI)I. Behavioral testing was performed on female hemizygotic R6/2 transgenic mice (n = 9) and female wild-type littermates (n = 22) between 5 and 14 weeks of age. Transgenic mice did not show an overt behavioral phenotyp...
In people with Huntington's disease, an expanded CAG repeat sequence on the HTT gene confers a toxic...
In people with Huntington's disease, an expanded CAG repeat sequence on the HTT gene confers a toxic...
To determine the suitability of mouse models of disease for therapeutic trials, the models must be c...
Transgenic mice expressing exon 1 of the human Huntington’s disease (HD) gene carrying a 141–157 CAG...
Transgenic mice expressing exon 1 of the human Huntington’s disease (HD) gene carrying a 141–157 CAG...
Transgenic mice expressing exon 1 of the human Huntington’s disease (HD) gene carrying a 141–157 CAG...
Huntington's disease is caused by a single mutation on the HTT gene which produces an expansion in t...
Huntington's disease is caused by a single mutation on the HTT gene which produces an expansion in t...
Huntington's disease is caused by a single mutation on the HTT gene which produces an expansion in t...
Cognitive decline is apparent in the early stages of Huntington's disease and progressively worsens ...
Huntington's disease (HD) is an incurable neurodegenerative condition characterized by progressive m...
To determine the suitability of mouse models of disease for therapeutic trials, the models must be c...
To determine the suitability of mouse models of disease for therapeutic trials, the models must be c...
In people with Huntington's disease, an expanded CAG repeat sequence on the HTT gene confers a toxic...
In people with Huntington's disease, an expanded CAG repeat sequence on the HTT gene confers a toxic...
In people with Huntington's disease, an expanded CAG repeat sequence on the HTT gene confers a toxic...
In people with Huntington's disease, an expanded CAG repeat sequence on the HTT gene confers a toxic...
To determine the suitability of mouse models of disease for therapeutic trials, the models must be c...
Transgenic mice expressing exon 1 of the human Huntington’s disease (HD) gene carrying a 141–157 CAG...
Transgenic mice expressing exon 1 of the human Huntington’s disease (HD) gene carrying a 141–157 CAG...
Transgenic mice expressing exon 1 of the human Huntington’s disease (HD) gene carrying a 141–157 CAG...
Huntington's disease is caused by a single mutation on the HTT gene which produces an expansion in t...
Huntington's disease is caused by a single mutation on the HTT gene which produces an expansion in t...
Huntington's disease is caused by a single mutation on the HTT gene which produces an expansion in t...
Cognitive decline is apparent in the early stages of Huntington's disease and progressively worsens ...
Huntington's disease (HD) is an incurable neurodegenerative condition characterized by progressive m...
To determine the suitability of mouse models of disease for therapeutic trials, the models must be c...
To determine the suitability of mouse models of disease for therapeutic trials, the models must be c...
In people with Huntington's disease, an expanded CAG repeat sequence on the HTT gene confers a toxic...
In people with Huntington's disease, an expanded CAG repeat sequence on the HTT gene confers a toxic...
In people with Huntington's disease, an expanded CAG repeat sequence on the HTT gene confers a toxic...
In people with Huntington's disease, an expanded CAG repeat sequence on the HTT gene confers a toxic...
To determine the suitability of mouse models of disease for therapeutic trials, the models must be c...